Back to Search Start Over

Evaluation of Aerosol Delivery of Nanosuspension for Pre-clinical Pulmonary Drug Delivery

Authors :
Chiang Po-Chang
Alsup Jason
Lai Yurong
Hu Yiding
Heyde Bruce
Tung David
Source :
Nanoscale Research Letters, Vol 4, Iss 3, Pp 254-261 (2009)
Publication Year :
2009
Publisher :
SpringerOpen, 2009.

Abstract

Abstract Asthma and chronic obstructive pulmonary disease (COPD) are pulmonary diseases that are characterized by inflammatory cell infiltration, cytokine production, and airway hyper-reactivity. Most of the effector cells responsible for these pathologies reside in the lungs. One of the most direct ways to deliver drugs to the target cells is via the trachea. In a pre-clinical setting, this can be achieved via intratracheal (IT), intranasal (IN), or aerosol delivery in the desired animal model. In this study, we pioneered the aerosol delivery of a nanosuspension formulation in a rodent model. The efficiency of different dosing techniques and formulations to target the lungs were compared, and fluticasone was used as the model compound. For the aerosol particle size determination, a ten-stage cascade impactor was used. The mass median aerodynamic diameter (MMAD) was calculated based on the percent cumulative accumulation at each stage. Formulations with different particle size of fluticasone were made for evaluation. The compatibility of regular fluticasone suspension and nanosuspension for aerosol delivery was also investigated. The in vivo studies were conducted on mice with optimized setting. It was found that the aerosol delivery of fluticasone with nanosuspension was as efficient as intranasal (IN) dosing, and was able to achieve dose dependent lung deposition.

Details

Language :
English
ISSN :
19317573 and 1556276X
Volume :
4
Issue :
3
Database :
Directory of Open Access Journals
Journal :
Nanoscale Research Letters
Publication Type :
Academic Journal
Accession number :
edsdoj.1bad662490e44ee8882752789090db2b
Document Type :
article
Full Text :
https://doi.org/10.1007/s11671-008-9234-1